Mouse models with modified p53 sequences to study cancer and ageing

Cell Death and Differentiation

Volumn 10, Issue 4, 2003, Pages 443-450

  Clarke, A R ^a   Hollstein, M ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Ageing; Cre Lox; Murine; Neoplasia; p53; Transgenic

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

AGING; ALLELE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER SUSCEPTIBILITY; DRUG SPECIFICITY; EXPERIMENTAL MODEL; EXPERIMENTATION; GENE TARGETING; HUMAN GENETICS; HYPOTHESIS; KNOCKOUT MOUSE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, MUTANT STRAINS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE; MUS MUSCULUS; RODENTIA;

EID: 0038413785     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401188     Document Type: Review

References (78)

1. Hainaut P and Pfeifer GP (2001) TP53 mutational spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Carcinogenesis 22: 367-374
2. Hainaut P and Hollstein M (2000) P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77: 81-137
3. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutation 19: 607-614
4. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine AJ (1993) Gain of function mutations in p53. Nat. Genet. 4: 42-45
5. Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD (1998) An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Aced. Sci. USA 95: 5166-5171
6. Laviguer A, Maltby V, Mock D, Rossant J, Pawson T and Bernstein A (1989) High incidence of lung, bone, and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell Biol. 9: 3982-3991
7. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A and Donehower LA (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Gene. 9: 305-311
8. Bullock AN and Fersht AR (2001) Rescuing the function of mutant p53. Nat. Cancer Rev. 1: 68-76
9. Li B, Greenberg N, Stephens LC, Mayn R, Medina D and Rosen JM (1994) Preferential overexpression of a 172Arg->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Different. 5: 711-721
10. Li B, Murphy KL, Laucirica R, Kittrell F, Medina D and Rosen JM (1998) A transgenic mouse model for mammary carcinogenesis. Oncogene 16: 997-1007
11. Medina D, Ullrich R, Meyn R, Wiseman R and Donehower L (2002) Environmental carcinogens and p53 tumour-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis. Environ. Mol. Mutagen. 39: 178-183
12. Wang X-J, Greenhalgh DA, Jiang A, He D, Zhong L, Medina D, Brinkley BR, and Roop DR (1998) Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene 17: 35-45
13. Harvey M, McArthur MJ, Montgomery Jr. CA, Bradley A and Doenhower LA (1993a) Genetic background alters the spectrum of tumours that develop in p53-deficient mice. FASEB J. 7: 938-943
14. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
15. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS and Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
16. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
17. Armstrong JF, Kaufman MH, Harrison DJ and Clarke AR (1995) High frequency developmental abnormalities in p53 deficient mice consistent with acquired mutations. Curr Biol 5: 931-936
18. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT and Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 10: 175-180
19. Norimura T, Nomoto S, Katsuki M, Gondo Y and Kondo S (1996) p-53-dependent apoptosis suppresses radiation induced teratogenesis. Nat. Med. 2: 525-526
20. Hall PA and Lane DP (1997) Tumour suppressors: a developing role for p53?. Curr. Biol. 7: R144-R147
21. Jones SN, Roe AE, Donehower LA and Bradley A (1995) Rescue of embryonic lethality in Mdm-2 deficient mice by absence of p53. Nature 9: 206-208.
22. Hakem R, de la Pompa JL, Elia A, Potter J and Mak TW (1997) Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Gene. 16: 298-302
23. Parant J, Chavez-Reynes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of p53 suggests a nonoverlapping pathway with Mdm2 to regulate p53. Nat. Gene. 29: 92-95
24. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA (1994) Tumour spectrum analysis in p53-mutant mice. Cur. Biol. 1: 4-7
25. Purdie CA, Harrison, DJ, Peter A, Dobbie L, White S, Howie SEM, Salter DM, Bird CC, Wyllie AH, Hooper ML and Clarke AR. (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603-609
26. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A and Donehower LA (1993) Spontaneous and carcinogen induced tumorigenesis in p53 deficient mice. Nat. Gene. 5: 225-229
27. Kemp CJ, Wheldon T and Balmain A (1994) p53 deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Gene. 8: 66-69
28. Kemp CJ, Donehower LA, Bradley A and Balmain (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell 74: 813-822
29. Greenhalgh DA, Wang XJ, Donehower LA and Roop DR (1996) Paradoxical tumour inhibitory effect of p53 loss in transgenic mice expressing epidermal targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 56: 4413-4423
30. Wagner M, Greten FR, Weber CK, Koschnick S, Mattfeldt T, Deppert W, Kern H, Adler G and Schmid RM (2001) A murine tumour progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15: 286-293
31. Clarke AR, Cummings MC and Harrison DJ (1995) Interaction between murine germline mutations in p53 and APC predisposes to pancratic neoplasia but not to increased intestinal malignancy. Oncogene 11: 1913-1920
32. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ and Johnson DG (1998) Increased E2F1 activity induces skin tumours in mice heterozygous and nullizygous for p53. Proc. Natl. Acad. Sci. USA 95: 8858-8863
33. Landesman-Bollag E, Channavajhala PL, Cardiff RD and Seldin DC (1998) P53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 16: 2965-2974
34. Iozzo RV, Chakrani F, Perotti D, McQuillan DJ, Skorski T, Calbretta B and Eichstetter I (1999) Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. USA 96: 3092-3097
35. Conde C, Mark M, Oliver FJ, Huber A, de Murcia G and Menissier de Murcia J (2001) Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J 20: 3535-3543
36. Beneke R and Moroy T (2001) Inhibition of poly(ADP-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53-deficient mice. Oncogene 20: 8136-8141
37. Lim DS and Hasty P (1996) A mutation in mouse rad51 results in an early embryonic lethality that is suppressed by a mutation in p53. Mol. Cell. Biol. 16: 7133-7143
38. Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE and Leder P (1997) atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Gene. 16: 397-401
39. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D and Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9: 882-895
40. Clarke AR, Gledhill S, Hoper ML, Bird CC and Wyllie AH (1994) p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9: 1767-1773
41. Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH and Greaves M (1997) Absence of p53 promotes propagation of mutant cells following genotoxic damage. Oncogene 14: 523-531
42. Hendry JH, Cai WB, Roberts SA and Potten CS (1997) P53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat. Res. 148: 254-259
43. Hendry JH, Broadbent DA, Roberts SA and Potten CS (2000) Effects of deficiency in p53 or bcl-2 on the sensitivity of clonogenic cells in the small intestine to low dose rate irradiation. Int. J. Radiat. Biol. 76: 559-565
44. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C and Kolesnick R (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297
45. Sansom OJ and Clarke AR (2002) The ability to engage apoptosis does not predict long term enterocyte survival in p53 and Msh2 deficient mice. Oncogene 21: 5934-5939
46. Nishino H, Knoll A, Buettner VL, Frisk CS, Maruta Y, Haavik J and Sommer SS (1995) P53 wild type and p53 nullizygous big blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. Oncogene 11: 263-270
47. Clarke AR, Howard LA, Harrison DJ and Winton DJ (1997) p53 mutation frequency and apoptosis in the murine small intestine. Oncogene 14: 2015-2018
48. Giese H, Snyder WK, van Oostrom C, van Steeg H, Dolle ME and Vijg J (2002) Age related mutation accumulation at the lacZ reporter locus in normal and tumour tissues of Trp53-deficient mice. Mutat. Res. 514: 153-163
49. Johnstone RW, Ruefli AA and Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164
50. Symonds H, Krell L, Remington L, Saenz-Robles M, Lowe S, Jacks T and Van Dyke T (1994) p53-dependent apoptosis suppresses tumour growth and progression in vivo. Cell 78: 703-711
51. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91
52. Hermeking H and Eick D (1994) Mediation of c-Myc induced apoptosis by p53. Science 265: 2091-2093
53. Pelengaris S, Khan M and Evan GI (2002) Suppression of myc-induced apoptosis in beta cells exposes multiple oncogenic properties of myc and triggers carcinogenic progression. Cell 109: 321-334
54. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinsn ES, Laurcirica R, Medina D, Naber SP and Jerry DJ (2000) Development of spontaneous mammary tumours in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol. 157: 2151-2159
55. 6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 12: 693-697
56. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA (1998) Retention of wild-type p53 in tumours from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17: 4657-4667
57. Toft NJ, Curtis LJ, Sansom OJ, Leitch AL, Te Riele H, Wyllie AH, Arends MJ, and Clarke AR (2002) Heterozygosity for p53 promotes microsatellite instability on an Msh2 deficient background. Oncogene 21: 6299-6306
58. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS and Medina D (2000) A mammary-specific model demonstrates the role of the p53 tumour suppressor gene in tumour development. Oncogene 19: 1052-1058
59. Marino S, Vooijs M, van Der Gulden H, Jonkers J and Berns A (2000) Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14: 994-1004
60. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M and Berns A (2001) Synergistic tumour suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Gene. 29: 418-425
61. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A and Donehower LA (2002) P53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53
62. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ and Lowe SW (2002) Oncogenic ras and p53 co-operate to induce cellular senescence. Mol. Cell Biol. 22: 3497-3508
63. Schmitt CA, Friedman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346
64. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK and Lozano G (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. USA 97: 4174-4179
65. Jimenez GS, Mister M, Stommel JM, Beeche M, Barcarse EA, Zhang, XQ, O'Gorman S. and Wahl GM (2000) A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26: 37-43
66. DeVries A, Flores ER, Miranda B, Hsieh H-M, van Oostrom CTM, Sage J and Jacks T (2002) Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. 99: 2948-2953
67. Luo J-L, Yang Q, Tong W-M, Hergenhahn M, Wang Z-Q and Hollstein M (2001a) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20: 320-328
68. Luo J-L, Tong W-M, Yoon J-H, Hergenhahn M, Koomagi R, Yang Q, Galendo D, Pfeifer GP, Wang Z-Q and Hollstein M (2001b) UV-induced DNA damage and mutations in Hupki (Human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res. 61: 8158-8163
69. Hahn WC and Weinberg RA (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2: 331-341
70. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
71. Brachmann RK, Yu K, Eby Y, Pavletich NP and Boeke JD (1998) Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17: 1847-1859
72. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vovsden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PN, Crook T, Kaelin WG Jr (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Gene. 25: 47-53
73. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimdo Y, Saito S, Gostissa M, Coen S, Marchetli A, Del Sal G, Piaggio G, Fanicolli M, Appella E, Soddo S (2002) Homeodomain-interactive protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4: 11-19
74. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H and Schmitz ML (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4: 1-10
75. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y and Taya Y (2000) P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser46-phosphorylated p53. Cell 102: 849-862
76. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C et al (2002) Amplification of PPM1D in human tumours abrogates p53 tumour-suppressor activity. Nat. Gene. 31: 210-215
77. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG and Hogenesch JB (2002) Large scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. 99: 4465-4470
78. Gillet R, Grimber G, Bennoun M, Caron de Fromentel C, Briand P and Joulin V (2000) The consequence of p53 overexpression for liver tumour development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene 19: 3498-3507